Cannabinoids as potential new therapy for the treatment of gliomas

  title={Cannabinoids as potential new therapy for the treatment of gliomas},
  author={Daniela Parolaro and Paola Massi},
  journal={Expert Review of Neurotherapeutics},
  pages={37 - 49}
  • D. ParolaroP. Massi
  • Published 1 January 2008
  • Medicine, Biology
  • Expert Review of Neurotherapeutics
Gliomas constitute the most frequent and malignant primary brain tumors. Current standard therapeutic strategies (surgery, radiotherapy and chemotherapeutics, e.g., temozolomide, carmustin or carboplatin) for their treatment are only palliative and survival diagnosis is normally 6–12 months. The development of new therapeutic strategies for the management of gliomas is therefore essential. Interestingly, cannabinoids have been shown to exert antiproliferative effects on a wide spectrum of cells… 

Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233

Findings indicate that structural refinement of KM-233 to improve its biopharmaceutical properties may lead to a novel and efficacious treatment for GBM.

Synthetic Cannabinoids Influence the Invasion of Glioblastoma Cell Lines in a Cell- and Receptor-Dependent Manner

Cannabinoids can influence glioblastoma cell invasion in a receptor and cell type specific manner that is independent of proliferation and apoptosis, and can potentially be used in the future as an addition to current therapy.

Cannabinoids as seed compounds for the cancer treatment

This review presents current knowledge relating to the possible application of cannabinoids as seed compounds for cancer treatment, and the anticancer effects of cannabinoids, the underlying mechanisms, and their future possible use in cancer treatment are presented.

Update on the endocannabinoid system as an anticancer target

This review covers literature from the past decade which highlights the potential of targeting the ECS for cancer treatment, and the levels of endocannabinoids and the expression of their receptors in several types of cancer are discussed, along with the signaling pathways involved in theendocannabinoid antitumor effects.

Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies?

This review critically discusses the pharmacology of CB receptor activation as a novel therapeutic anticancer strategy in terms of ligand selectivity, tissue specificity and potency.

Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival

Cannabidiol, the second most abundant plant-derived cannabinoid, in combination with Δ9-THC is tested and it is suggested that the addition of cannabidiole may improve the overall effectiveness of Δ9 -THC in the treatment of glioblastoma in cancer patients.

Preparation and characterization of D 9-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines

The development of D-tetrahydrocannabinol biodegradable microspheres as an alternative delivery system for cannabinoid parenteral administration is proposed and the micro Spheres were able to inhibit cancer cell proliferation during the nine-day study period.

Preparation and characterization of Δ9-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines

The development of Δ9-tetrahydrocannabinol biodegradable microspheres as an alternative delivery system for cannabinoid parenteral administration is proposed and theMicrospheres were able to inhibit cancer cell proliferation during the nine-day study period.

Cannabidiol: State of the art and new challenges for therapeutic applications.



Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.

It is shown that the CB(1) and theCB(2) receptor are expressed in normal skin and skin tumors of mice and humans and support a new therapeutic approach for the treatment of skin tumors.

Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.

It is shown that local administration of the selective CB(2) agonist JWH-133 at 50 microg/day to Rag-2(-/-) mice induced a considerable regression of malignant tumors generated by inoculation of C6 glioma cells, and showed that selective activation of the CB( 2) receptor signaled apoptosis via enhanced ceramide synthesis de novo.

Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma

Evidence is provided that KM-233 shows promising efficacy against humanglioma cell lines in both in vitro and in vivo studies, minimal toxicity to healthy cultured brain tissue, and should be considered for definitive preclinical development in animal models of glioma.

Molecularly targeted therapy for malignant glioma

The authors discussed the current understanding of molecular pathogenesis and the development of molecularly targeted therapies in malignant glioma, and suggested novel clinical trial designs and endpoints may increase the efficiency of new drug evaluation.

Cannabinoids Induce Glioma Stem-like Cell Differentiation and Inhibit Gliomagenesis*

It is demonstrated that cannabinoids target glioma stem-like cells, promote their differentiation, and inhibit gliomagenesis, thus giving further support to their potential use in the management of malignant gliomas.

A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme

The fair safety profile of THC, together with its possible antiproliferative action on tumour cells reported here and in other studies, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids.

Arachidonylethanolamide Induces Apoptosis of Human Glioma Cells through Vanilloid Receptor‐1

It is observed that AEA induced apoptosis in long-term and recently established glioma cell lines via aberrantly expressed vanilloid receptor-1 (VR1), which shows that the selective targeting of VR1 by AEA or more stable analogues is an attractive research area for the treatment of gliomas.

Novel immunotherapeutic approaches to glioma.

  • R. Yamanaka
  • Medicine, Biology
    Current opinion in molecular therapeutics
  • 2006
Dendritic cell- and peptide-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma; the therapy appears to be safe and without major side effects.

Temozolomide: realizing the promise and potential

It is suggested that temozolomide, as currently used, has limited efficacy in treating refractory malignant infiltrative brain tumors, and survival benefit is, at best, a few weeks longer than that with procarbazine.